P
Paques Biomaterials
Producing a biodegradable plastic from waste(water) streams
About Paques Biomaterials
Paques Biomaterials has developed a technology that utilizes microbes to produce Polyhydroxyalkanoates (PHA), a biopolymer that is both biobased and biodegradable, from organic waste streams. The company is currently scaling up its production capabilities, with a pilot plant already in operation and a full-scale production facility in development in collaboration with ESKA.
Read full description
The company's primary product, Caleyda®, is a PHA-based bioplastic that serves as a sustainable alternative to traditional fossil-fuel-based plastics. This material has a wide range of applications, including in composites, 3D printing, adhesives, films, and various coatings. Paques Biomaterials' business model is centered on the production and sale of Caleyda® to businesses seeking to reduce their environmental impact and transition to more circular material sourcing.
The company's target market includes industries that are heavy users of plastics and are under pressure to adopt more sustainable practices. By converting waste into a valuable resource, Paques Biomaterials is positioning itself as a key player in the circular economy.
At a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Balk, Netherlands
- Employees
- 32
- Open positions
- 1
- Dealroom signal
- 86.8/100
- Sub-industry
- Water, Waste Solution
- Sector
- Energy, Recycling, Biotechnology, Water Treatment, Biomaterials, Plastic, Sustainable Packaging, Sustainable Development Goals, Wastewater Treatment
- Technology
- Hardware, Deep Tech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| EARLY VC✓Equity / VC | Jan 2024 | $15M | $62M | Invest-NL · NOM - Northern Netherlands Regional Development Agency | ↗ |
Growth signals
Latest recorded traffic for Paques Biomaterials is 200 monthly website visits, down 88.2% over the last three months. Paques Biomaterials's team grew 28% over the past year.
Open positions
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A2 investors entered at this stage
Invest-NL
NOM - Northern Netherlands Regional Development Agency
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Paques Biomaterials on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Paques Biomaterials’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.